Provided by Tiger Trade Technology Pte. Ltd.

Unicycive Therapeutics, Inc.

5.63
+0.18003.30%
Post-market: 5.61-0.0200-0.36%19:30 EDT
Volume:1.01M
Turnover:5.69M
Market Cap:156.83M
PE:-3.61
High:5.77
Open:5.51
Low:5.50
Close:5.45
52wk High:8.74
52wk Low:3.71
Shares:27.86M
Float Shares:25.82M
Volume Ratio:1.42
T/O Rate:3.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5585
EPS(LYR):-1.6715
ROE:-101.07%
ROA:-40.59%
PB:2.94
PE(LYR):-3.37

Loading ...

Unicycive Therapeutics - FDA Has not Conducted Inspection of Third-party Manufacturing Vendor for Resubmitted Nda

THOMSON REUTERS
·
Jun 30

Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)

GlobeNewswire
·
Jun 30

NASDAQ Trade Halt Halt News Pending at 07:00 Am

Reuters
·
Jun 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jun 27

Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026

Reuters
·
Jun 22

Unicycive Expands At-The-Market Equity Offering Program

TIPRANKS
·
Jun 06

Unicycive Therapeutics Raises ATM Offering of Shares

MT Newswires Live
·
Jun 06

BRIEF-Unicycive Therapeutics - Files Base Prospectus To Offer Up To $150 Million In Securities - SEC Filing

Reuters
·
Jun 06

Unicycive Therapeutics files $150M mixed securities shelf

TIPRANKS
·
Jun 06

Unicycive Therapeutics - Files Sales Agreement Prospectus to Offer up to $50 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 06

Unicycive publishes corporate presentation on OLC hyperphosphatemia treatment for dialysis patients

Reuters
·
Jun 05

Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark

Dow Jones
·
Jun 02

Unicycive Therapeutics management to meet virtually with Piper Sandler

TIPRANKS
·
May 28

Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears

Simply Wall St.
·
May 16

Unicycive Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline

Reuters
·
May 14

Unicycive Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
May 13

Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate

Benzinga Earnings
·
May 12

Unicycive Therapeutics Q1 net loss widens on warrant liability

Reuters
·
May 12

Unicycive Therapeutics Q1 Income From Operations USD -8.437 Million

THOMSON REUTERS
·
May 12